Instanosis is committed to building strategic partnerships with diagnostic manufacturers, distributors, and healthcare organizations.
Distributors and GPOs
Instanosis partners with distributors and GPOs to expand access to life-saving drug detection and research tools across clinical, community, and laboratory settings. We offer the most accurate and sensitive test kits on the market, independently validated and field-tested, at a price point that ensures broad accessibility. Our goal is to simplify procurement and empower organizations with the tools they need to detect emerging drug threats, respond rapidly, and protect the communities they serve.
Harm Reduction
Instanosis supports harm reduction organizations by providing tools that enable safer substance use and prevent overdose deaths. Our test strips help outreach teams and service providers quickly identify the presence of fentanyl, xylazine, and nitazenes in drugs or paraphernalia, empowering people who use drugs to make informed decisions. By enabling rapid, on-site testing without lab equipment, we help reduce the risk of accidental exposure to lethal substances and support frontline efforts to save lives and promote safer use practices.
Healthcare and Research
Instanosis partners with healthcare and research organizations to support the early detection, monitoring, and study of synthetic opioids and emerging drug threats. We provide validated, easy-to-use test kits for use in clinical care, harm reduction programs, and field research, as well as high-quality reagents for laboratory-based studies. Our collaborations aim to improve public health outcomes by enabling rapid, accurate screening in hospitals, addiction treatment centers, and community outreach settings. Through these partnerships, we help generate real-world data, support grant-funded research, and inform evidence-based strategies to address the evolving overdose crisis.
Diagnostic Manufacturers
Instanosis partners with diagnostic manufacturers to co-develop and scale high-sensitivity lateral flow assays targeting emerging drug threats such as fentanyl, xylazine, and nitazenes. We offer proprietary antibodies, antigens, and nanoparticle conjugates specifically validated for use in rapid test formats, along with extensive technical expertise in assay design, optimization, and validation. By collaborating from early development through commercialization, we help manufacturers accelerate product timelines, enhance analytical performance, and expand into high-impact markets, including harm reduction, emergency medicine, and forensic toxicology.
Our collaborative approach offers partners a unique opportunity to expand their portfolios, accelerate time to market, and generate meaningful revenue while addressing critical public health challenges.
✓deep expertise in lateral flow and immunoassay development
✓proven track record of product validation
✓access to extensive scientific and clinical resources.